COMPANY PROFILE

Seragon Pharmaceuticals

Explore full profile

Develops small-molecule drugs for the treatment of estrogen receptor dependent breast cancer

Irvine, United StatesFounded 2013Biotech & Life Sciences

Valuation $100–250M Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Seragon Pharmaceuticals

Seragon Pharmaceuticals is a global biotechnology company specializing in innovative biomedical solutions aimed at improving human health and longevity. The company operates in the fast-paced and evolving home health market, leveraging its scientific expertise to identify and address gaps in modern healthcare. Seragon's core focus areas include immunology, gene therapy, and aging, providing cutting-edge treatments and therapies to enhance the immune system and combat serious diseases. The business model revolves around research and development, clinical trials, and commercialization of advanced biomedical products. Revenue is generated through the sale of these specialized treatments and therapies to healthcare providers, research institutions, and directly to consumers. Seragon's clients range from individual patients to large healthcare organizations, making it a key player in the biotechnology and home health sectors.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2013
Headquarters: Irvine, United States
Employees: 12
Open positions: None listed
Dealroom signal: 47.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Longevity, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b, b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Jul 2014	$725M	—	Genentech	—
SERIES A✓Equity / VC	Oct 2013	$30M	$120M	The Column Group · OrbiMed · Aisling Capital · venBio Partners	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Seragon Pharmaceuticals website traffic

Latest recorded traffic for Seragon Pharmaceuticals is 0 monthly website visits. Seragon Pharmaceuticals's team grew 100% over the past year.

Latest monthly visits0 1-year team growth+100%

Monthly website visitsApr 2016–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EPEpiternaDeveloping affordable products that can safely slow the ageing process to prevent age-related disease, delay functional decline, and extend life	Epalinges, Switzerland	Operational	5	$11M	$44M
MBMitra bioNon-invasive diagnostics for skincare and therapeutics development	London, United Kingdom	Operational
GTGyroscope TherapeuticsDeveloping one-time gene therapies for retinal diseases	London, United Kingdom	Acquired
STSenolytic TherapeuticsA discovery-stage biotech developing novel medicines that target senescent cells	Barcelona, Spain	Closed
AFAFFiRiSBringing vaccines to chronic disease	Vienna, Austria	Operational
RPRefoxy PharmaRefoxy is a Pharmaceutical company discovering medicines to treat age-related diseases and extend the years of healthy living	Cologne, Germany	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational